Accéder au contenu
Merck

Principaux documents

Voir toute la documentation

D9035

Diazoxide

≥98% (TLC), powder, ATP-sensitive K⁺ channel activator

Synonyme(s) :

7-Chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

Formule empirique (notation de Hill) :
C8H7ClN2O2S
Numéro CAS:
364-98-7
Poids moléculaire :
230.67
NACRES:
NA.77
PubChem Substance ID:
24277831
UNSPSC Code:
12352119
EC Number:
206-668-1
MDL number:
MFCD00078578
Form:
powder
Quality level:
100
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

Nom du produit

Diazoxide,

form

powder

Quality Level

100

solubility

0.1 M NaOH: soluble, H2O: insoluble, methanol: soluble

originator

Schering Plough

SMILES string

CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1

InChI

1S/C8H7ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-4H,1H3,(H,10,11)

InChI key

GDLBFKVLRPITMI-UHFFFAOYSA-N

Gene Information

human ... KCNA1(3736), KCNJ11(3767), KCNJ8(3764), KCNMA1(3778)
mouse ... Kcnj1(56379), Kcnj11(16514)
rat ... Gria1(50592), Kcna1(24520), Kcnj1(24521), Kcnj11(83535), Kcnj8(25472)

General description

Diazoxide is a nondiuretic benzothiadiazine, which is used for the treatment of hypoglycemia, von Gierke′s disease, acute and malignant hypertension. It acts as a beta cell KATP channel opener. Diazoxide prevents the secretion of insulin.

Application

Diazoxide has been used for diazoxide infusion. It has also been used to prevent depolarization for K+-induced exocytosis.

Biochem/physiol Actions

Selective ATP-sensitive K+ channel activator in both vascular smooth muscle and pancreatic β-cells; antihypertensive.

Features and Benefits

This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Schering Plough. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Still not finding the right product?

Explore all of our products under

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Classe de stockage

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number
BCCL3550
WXBF2299V
BCCF3412
BCCB0466
BCBX4929

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Contenu apparenté

Product Information Sheet - D9035

Product Information Sheet

N D'hahan et al.
Proceedings of the National Academy of Sciences of the United States of America, 96(21), 12162-12167 (1999-10-16)
The pharmacological phenotype of ATP-sensitive potassium (K(ATP)) channels is defined by their tissue-specific regulatory subunit, the sulfonylurea receptor (SUR), which associates with the pore-forming channel core, Kir6.2. The potassium channel opener diazoxide has hyperglycemic and hypotensive properties that stem from
T Grimmsmann et al.
British journal of pharmacology, 123(5), 781-788 (1998-04-16)
1. The direct effects of diazoxide on mitochondrial membrane potential, Ca2+ transport, oxygen consumption and ATP generation were investigated in mouse pancreatic B-cells and rat liver mitochondria. 2. Diazoxide, at concentrations commonly used to open adenosine 5'-triphosphate (ATP)-dependent K+-channels (K(ATP)
Glucose-dependent granule docking limits insulin secretion and Is decreased in human type 2 diabetes
Gandasi NR, et al.
Cell Metabolism, 27(2), 470-478 (2018)
Afficher tous les articles scientifiques apparentés